TNFRSF13B and Autoimmunity: As already demonstrated [12, 34] CVID patients carrying TNFRSF13B heterozygous mutations had a higher prevalence of autoimmunity compared with patients with wild-type TNFRSF13B (61.5% versus 23%, p = 0.005) (Figure 2(a)).